| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R21CA256902 | The role of Epstein Barr Virus and Human Papilloma Virus Co-infection in Conjunctival Squamous Cell Carcinoma. | 000 | 2 | NIH | 10/29/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $3,678,099 ) |
| | 2024 | 2024 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | OT2CA278681 | PROMINENT - IARC | 002 | 1 | NIH | 9/13/2024 | $33,503 |
| | 2024 | 2024 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | OT2CA278681 | PROMINENT - IARC | 001 | 1 | NIH | 9/5/2024 | $469,419 |
| | 2024 | 2024 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R37CA275824 | A novel, one stop, affordable, point of care and artificial intelligence supported system of screening, triage and treatment selection for cervical cancer and precancer in the LMICs | 000 | 2 | NIH | 9/3/2024 | $491,802 |
| | 2024 | 2024 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 ave Tony Garnier | LYON | LYON | | | FRA | NU58DP007177 | The IARC Handbooks of Cancer Prevention - Evidence-based evaluations of primary and secondary cancer prevention approaches | 01 | 3 | CDC | 8/14/2024 | $0 |
| | 2024 | 2024 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R01CA033193 | IARC Monographs on the Identification of Carcinogenic Hazards to Humans | 000 | 42 | NIH | 7/22/2024 | $836,241 |
| | 2024 | 2024 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R01CA033193 | IARC Monographs on the Identification of Carcinogenic Hazards to Humans | 000 | 42 | NIH | 7/22/2024 | $104,500 |
| | 2024 | 2024 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | U01CA289226 | The Opioid Cohort Consortium (OPICO) to investigate the effects of using opioids on cancer risk | 000 | 1 | NIH | 3/21/2024 | $586,334 |
| | 2024 | 2024 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | U01CA257679 | InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies. | 000 | 4 | NIH | 7/31/2024 | $510,942 |
| | 2024 | 2024 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R01CA262164 | The Lung EArly Proteins project: A LEAP toward implementing biomarkers in lung cancer screening | 000 | 3 | NIH | 8/8/2024 | $452,301 |
| | 2024 | 2024 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 ave Tony Garnier | LYON | LYON | | | FRA | NU58DP007177 | The IARC Handbooks of Cancer Prevention - Evidence-based evaluations of primary and secondary cancer prevention approaches | 00 | 3 | CDC | 7/2/2024 | $200,000 |
| | 2024 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | UH3CA202721 | Development, field testing and evaluation of the efficacy of a hand-held, portable and affordable thermo-coagulator to prevent cervical cancer in low- and middle-income countries | 000 | 5 | NIH | 7/12/2024 | -$6,943 |
| | 2024 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | OT2CA278681 | PROMINENT - IARC | 000 | 1 | NIH | 6/6/2024 | $0 |
| | 2024 | 2021 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R01DE025712 | The role of germline and somatic DNA mutations in oral and oropharyngeal cancers | 000 | 5 | NIH | 10/24/2023 | $0 |
| | 2024 | 2021 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | UH3CA202730 | Development and clinical validation of a multi-type HPV E6/E7 oncoprotein test for cervical cancer screening and triage in low- and middle-income countries | 000 | 5 | NIH | 2/1/2024 | $0 |
| | 2024 | 2020 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R03CA245979 | Evaluating risk prediction models for use in lung cancer screening in diverse populations around the world | 000 | 1 | NIH | 11/7/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,921,581 ) |
| | 2023 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R01CA033193 | IARC Monographs on the Identification of Carcinogenic Hazards to Humans | 000 | 41 | NIH | 7/24/2023 | $880,253 |
| | 2023 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 ave Tony Garnier | LYON | province | | | FRA | NU58DP007177 | The IARC Handbooks of Cancer Prevention - Evidence-based evaluations of primary and secondary cancer prevention approaches | 00 | 2 | CDC | 4/28/2023 | $200,000 |
| | 2023 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | UH3CA202721 | Development, field testing and evaluation of the efficacy of a hand-held, portable and affordable thermo-coagulator to prevent cervical cancer in low- and middle-income countries | 002 | 5 | NIH | 8/22/2023 | $0 |
| | 2023 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | OT2CA278681 | PROMINENT - IARC | 001 | 1 | NIH | 8/4/2023 | $450,879 |
| | 2023 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | UH3CA202721 | Development, field testing and evaluation of the efficacy of a hand-held, portable and affordable thermo-coagulator to prevent cervical cancer in low- and middle-income countries | 000 | 5 | NIH | 12/2/2022 | $442,901 |
| | 2023 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R01CA262164 | The Lung EArly Proteins project: A LEAP toward implementing biomarkers in lung cancer screening | 000 | 2 | NIH | 8/17/2023 | $451,746 |
| | 2023 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R01CA033193 | IARC Monographs on the Identification of Carcinogenic Hazards to Humans | 000 | 41 | NIH | 7/24/2023 | $110,000 |
| | 2023 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | U01CA257679 | InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies. | 000 | 3 | NIH | 8/3/2023 | $529,273 |
| | 2023 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R01CA244559 | African Breast Cancer - Disparities in Outcomes - Plus (ABC-DO Plus) | 000 | 4 | NIH | 4/24/2023 | $337,216 |
| | 2023 | 2023 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R37CA275824 | A novel, one stop, affordable, point of care and artificial intelligence supported system of screening, triage and treatment selection for cervical cancer and precancer in the LMICs | 000 | 1 | NIH | 8/10/2023 | $519,313 |
| | 2023 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | OT2CA278681 | PROMINENT - IARC | 000 | 1 | NIH | 5/26/2023 | $0 |
| | 2023 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 ave Tony Garnier | LYON | province | | | FRA | NU58DP007177 | The IARC Handbooks of Cancer Prevention - Evidence-based evaluations of primary and secondary cancer prevention approaches | 00 | 2 | CDC | 4/28/2023 | $0 |
| | 2023 | 2020 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | UH3CA202721 | Development, field testing and evaluation of the efficacy of a hand-held, portable and affordable thermo-coagulator to prevent cervical cancer in low- and middle-income countries | 001 | 5 | NIH | 8/22/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $3,526,582 ) (Continued on the next page) |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | R03DE030257 | Germline risk of oral and oropharyngeal cancers across diverse populations | 001 | 2 | NIH | 7/29/2022 | $108,394 |
| | 2022 | 2022 | Centre International De Recherche Sur Le Cancer | 150 Cours Albert Thomas | LYON | province | | | FRA | NU58DP007177 | The IARC Handbooks of Cancer Prevention - Evidence-based evaluations of primary and secondary cancer prevention approaches | 00 | 1 | CDC | 5/18/2022 | $200,000 |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | R01CA033193 | IARC Monographs on the Identification of Carcinogenic Hazards to Humans | 001 | 40 | NIH | 8/25/2022 | $870,000 |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | R01CA262164 | The Lung EArly Proteins project: A LEAP toward implementing biomarkers in lung cancer screening | 000 | 1 | NIH | 9/8/2022 | $430,982 |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | U01CA257679 | InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies. | 000 | 2 | NIH | 8/23/2022 | $529,422 |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | OT2CA278681 | PROMINENT - IARC | 000 | 1 | NIH | 6/22/2022 | $391,529 |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | UH3CA202721 | Development, field testing and evaluation of the efficacy of a hand-held, portable and affordable thermo-coagulator to prevent cervical cancer in low- and middle-income countries | 003 | 5 | NIH | 9/9/2022 | $0 |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | UH3CA202721 | Development, field testing and evaluation of the efficacy of a hand-held, portable and affordable thermo-coagulator to prevent cervical cancer in low- and middle-income countries | 000 | 5 | NIH | 1/28/2022 | $442,901 |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | R21CA256902 | The role of Epstein Barr Virus and Human Papilloma Virus Co-infection in Conjunctival Squamous Cell Carcinoma. | 001 | 2 | NIH | 7/1/2022 | $90,081 |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | R01CA244559 | African Breast Cancer - Disparities in Outcomes - Plus (ABC-DO Plus) | 000 | 3 | NIH | 4/7/2022 | $231,503 |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | R01CA244559 | African Breast Cancer - Disparities in Outcomes - Plus (ABC-DO Plus) | 001 | 3 | NIH | 9/19/2022 | $124,378 |
| | 2022 | 2022 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | R01CA033193 | IARC Monographs on the Identification of Carcinogenic Hazards to Humans | 001 | 40 | NIH | 8/25/2022 | $100,449 |
| | 2022 | 2021 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | R01CA033193 | IARC Monographs on the Identification of Carcinogenic Hazards to Humans | 000 | 39 | NIH | 1/18/2022 | $6,265 |
| | 2022 | 2021 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | R21CA256902 | The role of Epstein Barr Virus and Human Papilloma Virus Co-infection in Conjunctival Squamous Cell Carcinoma. | 000 | 1 | NIH | 1/11/2022 | $0 |
| | 2022 | 2021 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | UH3CA202721 | Development, field testing and evaluation of the efficacy of a hand-held, portable and affordable thermo-coagulator to prevent cervical cancer in low- and middle-income countries | 002 | 5 | NIH | 9/9/2022 | $0 |
| | 2022 | 2021 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 150 COURS ALBERT THOMAS | LYON | | | | FRA | R03DE030257 | Germline risk of oral and oropharyngeal cancers across diverse populations | 000 | 1 | NIH | 1/14/2022 | $0 |
| | 2022 | 2020 | CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER | 25 AVE TONY GARNIER | LYON | | | | FRA | U01CA033193 | Evaluation of Carcinogenic Risks to Humans | 000 | 38 | NIH | 1/18/2022 | -$6,265 |
|
